Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by SanFrancisco99on Aug 07, 2014 5:30pm
232 Views
Post# 22819904

RE:RE:RE:OK Don and Julie: How About An Update????

RE:RE:RE:OK Don and Julie: How About An Update????I'm curious too.

The only information I have seen about the post-hoc meta analysis of MACE that was worrying was a statement in one of the articles in Seeking Alpha that said that the MACE data was only based on about 60 patients....

Assuming this is true, I personally thought that that information was probably outweighed by the diabetes MACE data in the July 23rd news release.  That MACE data (if I remember right) was based upon 200 patients (across two studies).  Thus, the sample size is much larger and hence it should be much more reliable data.

Of course, I'm out of my comfort zone as I am not a scientist.  But other than that, I'm not aware of any data that seriously calls into question the MACE findings.  That doesn't mean it doesn't exist, it just means I have not seen it.  Hence, I'm curious if I missed something.




Bullboard Posts